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Background and aims: Extracts from oat (Avena Sativa) herb may benefit cognitive 
performance. This study investigated whether Neuravena®, an oat herb extract, could acutely 
improve responses to the Stroop Colour-Word test, a measure of attention and concentration 
and the ability to maintain task focus.  
Subjects and Methods: Elderly volunteers with below average cognitive performance 
consumed single doses (0, 1600 and 2400 mg) of oat herb extract at weekly intervals in a 
double-blind, randomized cross-over comparison;. Resting blood pressure (BP) was assessed 
before and after supplementation and a Stroop test was performed. 
Results: Significantly fewer errors were made during the colour naming component of the 
Stroop test after consuming the 1600 mg dose than after the 0 mg or 2400 mg doses (F (1,36) 
= 18.85, P<.001). In 7 subjects with suspected cognitive impairment, Stroop interference 
score was also improved by the 1600 mg dose compared to 0 and 2400 mg doses (F (1,34) = 
2.40, P < .01). Resting BP was unaffected by supplementation.  
Conclusion: Taking 1600 mg of oat herb extract may acutely improve attention and 
concentration and the ability to maintain task focus in older adults with differing levels of 







Avena sativa (oat) herb, in its various forms and extracts, has been traditionally known for its 
physical and psychological fortifying properties. Proposed beneficial effects include: reduced 
risk of heart disease, reduced depressive symptoms, raised energy levels, increased ability to 
cope with stress, reduced anxiety, and increased physical performance 1, 2. However, many of 
these benefits are yet to be substantiated by rigorous scientific enquiry 2. 
Studies in rodents have shown that an oat herb extract, Neuravena® (EFLA® 955) can 
increase learning ability and mental alertness. Schellekens et al 2009 3 investigated the effect 
of supplementing rat diets for seven weeks with either 10 or 100 g/kg of body weight/day of 
Neuravena®. This study demonstrated that a dose of 10 g/kg of body weight/day improved 
general learning performance, seemingly due to enhanced alertness and improved stress 
coping abilities, pro-social behaviour and enhanced mood, suggesting the extract could 
support active rather than passive stress coping behaviour. 
In humans, a single 2500 mg dose of Neuravena® was found to decrease delta and theta 
electrical brain wave activity and increase alpha2 wave activity 4, effects consistent with 
increased mental alertness.  
The current study aimed to explore the effects of oral Neuravena® on concentration and 
alertness, using the Stroop colour-word test in older adults with below average cognitive 
function, and to determine whether any observed effects were dose-dependent. 
Materials and Methods 
The study was approved by the University of South Australia’s Human Research Ethics 
committee and volunteers provided written, informed consent prior to commencing the trial. 





One hundred and eighty five volunteers were screened at the Nutritional Physiology Research 
Centre, Adelaide for inclusion in the study. Volunteers were recruited if they were aged 50 
years or above, healthy, not taking medications or supplements likely to affect the outcome of 
the study and assessed as having below average cognitive performance (DemTect® score 
between 9-16 points5. Of those screened, 36 subjects met the selection criteria and completed 
the trial. 
Supplements 
Neuravena® (wild green oat extract EFLA® 955) was obtained from Frutarom Switzerland 
Ltd and was manufactured using green, rapidly dried, aerial parts of Avena sativa L., 
harvested just before it is in full flower. It is a dry powder comprising an ethanol (30% w/w) 
extract of the above ground (green) parts of a selected variety of Avena sativa (3.5:1 
concentration), dispensed as 400mg capsules together with 28% (w/w) Maltodextrinum 
Ph.Eur. as a carrier and 2% (w/w) silica colloidalis anhydrica Ph.Eur. 
Participants were allocated to consume each of two doses of Neuravena® (1600 and 2400mg) 
and a placebo (0mg) (containing an inert filler and matched for appearance) at weekly 
intervals in a double-blind, randomized crossover comparison. 
Procedure 
On the first visit volunteers underwent cognitive screening using the DemTect® which is a 
screening tool used to identify Mild Cognitive Impairment (MCI) and early signs of 
dementia. Scores from 0-8 represent suspected dementia, 9-12 represent suspect MCI and 13-
18 represent normal cognitive performance. The median score in the current sample was 16 
which was also found by Kalbe et al., (2004). Participants with below average cognitive 
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performance but without suspected dementia (scores ranging from 9 to 16) were included in 
the current study. 
All subsequent visits were conducted on the same day of the week at the same time with a 
one-week washout between each session. All participants were instructed to fast for four 
hours before each session. On arrival resting supine blood pressure (BP) was measured 
following international guidelines 6. Following this volunteers consumed an oral supplement 
(0, 1600 or 2400 mg of Neuravena® in random order) with a glass of water and 1-2 hours 
later the BP measurement was repeated and a Stroop Colour Word test7 was performed. This 
test is designed to assess focussed attention and the ability to suppress task-irrelevant, 
habitual responses. During the test participants were given a sheet of colour names printed in 
incongruent coloured ink (for example, the word “blue” is printed in red ink). In the first trial, 
participants were asked to read all the words as fast and accurately as possible. In the second 
trial participants were asked to name the colour of each word, ignoring the word name itself. 
A measure of the Stroop interference effect was calculated using the ratio of the time taken to 
name colours divided by the time taken to read words. Numbers of corrected and uncorrected 
errors for each trial were also recorded. Therefore, higher scores on all metrics reflect poorer 
performance. 
Statistical Analyses 
One way repeated measures analysis of variance (ANOVA) was conducted on the responses 
to the Stroop test using dose as the within-subjects factor using Statistical Package for  the 
Social Sciences (SPSS) version 18 (Chicago, Illinois, United States of America). Fixed 
effects two-way ANOVAs were also conducted on outcomes including both dose and MCI 
status as factors. Where significant main effects were detected means were compared post 
hoc using a Bonferroni test. To produce the MCI status factor, subjects were grouped 
according to their DemTect® score. Seven participants scoring 9-12 were allocated to the 
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suspected MCI group; the remaining 29 participants scoring 12-16 were allocated to the non-
MCI group.  
Results 
Of the 36 subjects who completed the trial there were 22 females and 14 males with a mean 
age of 67 ± 8.6 years, mean DEMTECT score 14 ± 2, BMI 26.9 ± 3.8 kg/m2, systolic blood 
pressure 127 ± 19.2 mmHg, diastolic blood pressure 72.0 ± 7.5 mmHg and heart rate was 
63.0 ± 8.6 bpm. There were no significant treatment effects on clinic BP measures. 
The intervention results indicated a significant main effect of dose of oat herb extract, F (1, 
34) = 6.97, P < .05, and a dose x MCI status interaction, F (1,34) = 2.40, P < .01 on the 
Stroop interference score. Means and standard errors appear in Table 1. 
Those who were suspected to have probable MCI performed significantly better on the 
Stroop test (lower interference scores represent better performance) after taking the 1600 mg 
dose of supplement than after taking 0 mg or 2400 mg. 
There was also a main effect of dose for the number of errors made during the colour naming 
trial of the Stroop test, F (1,36) = 18.85, P<.001. However, there was no dose x MCI status 
interaction. Descriptive statistics appear in Table 2. There was a similar pattern of effect for 
all participants, regardless of MCI status, with significantly fewer errors made after 
consuming the 1600 mg supplement dose than after consuming the 0 mg or 2400 mg doses. 
Discussion 
This study demonstrated that acute supplementation with the oat herb extract could 
significantly improve the response to the Stroop Colour-Word test in people with lower 
cognitive status The Stroop test requires participants to inhibit a habitual response to reading 
colour names in order to name the colour in which they are printed. As such, high 
performance on this task, reflected in lower interference scores, represents high levels of 
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attention, concentration and task focus. It appears that 1600 mg of  oat herb extract acutely 
enhances these abilities among those with MCI, compared with placebo or 2400 mg. The 
number of errors made during the colour naming trial of the Stroop test reflects failures to 
inhibit task-irrelevant information. As such, this measure represents failures in attention, 
concentration and task focus. Results show that 1600 mg of oat herb extract reduced the 
number of errors made for all participants regardless of their cognitive status. These findings 
support the first indicative results in animals in which oat herb extract improved learning due 
to enhanced alertness and improved stress response in rats 3 and in humans 4  
The mechanism of effect remains unsubstantiated, however it has been suggested that green 
oat herb extracts have a significant inhibitory effect on monoamine oxidase B (MAO-B) and 
phosphodiesterase 4) (PDE 4) 8. These results were determined in in vitro bioactivity assays 
with an extract concentration of 50 µg/ml. Inhibition of MAO-B increases dopamine levels 
which are associated with better cognitive functioning. Inhibition of PDE 4 improves the 
levels cyclic adenosine monophosphate (cAMP), which is important for neurotransmitter 
actions. In addition, inhibition of this enzyme is believed to be associated with increases in 
endothelium dependant vasodilatation in the cerebral arteries 9, but this is yet to be explored 
in humans. Therefore it is possible that the observed improvement in Stroop performance is 
due to enhanced neurotransmission and cerebral perfusion. Further research is required to 
determine the precise mechanism of action, as well as to gather more clinical data on the 
effects of this green oat herb extract in humans. 
In conclusion, a 1600 mg oral dose of oat herb extract acutely improved attention, 
concentration and the ability to maintain task focus in older adults with differing levels of 




We would like to thank Frutarom Switzerland Ltd for providing supplements and financial 
support for this study. Frutarom provided input into the study design and in the writing of the 
manuscript. We are also grateful to Stella Papacharissiou, Joel Harman and Shane Moyle for 
their assistance with data collection. 
Disclosure Statement 




1. Abascal K, Yarnell E. Nervine herbs for treating anxiety. Alternative and 
Complementary Therapies. 2004;10:309-315. 
2. Bucci LR. Selected herbals and human exercise performance. American Journal of 
Clinical Nutrition. 2000;72(2):624S-636. 
3. Schellekens C, Perrinjaquet-Moccetti T, Wullschleger C, Heyne A. An extract from 
wild green oat improves rat behaviour. Phytotherapy Research. 2009;23(10):1371-
1377. 
4. Aydogan C, Schellekens C, Wullschleger C. Effects of a wild green oat extract on 
mental performance: a human clinical study using source density analysis of the 
human EEG. African Journal of Tradititional, Complementary and Alternative 
Medicine. 2009;6:478-479. 
5. Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening 
test to support the diagnosis of mild cognitive impairment and early dementia. Int J 
Geriatr Psychiatry. 2004;19:136-143. 
9 
 
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure. Hypertension. 2003;42(6):1206-1252. 
7. Dodrill CB. A neuropsychological battery for epilepsy. Epilepsia. 1978;19:611-623. 
8. Moccetti T, Wullschleger C, Schmidt A, et al. Bioactivity-based development of a 
wild green oat (Avena sativa L.) extract in support of mental health disorders. 
Phytopharmaka und Phytotherapie. Vol Berlin2006:s25-S26. 
9. Birk S, Edvinsson L, Olesen J, Kruuse C. Analysis of the effects of phosphodiesterase 





Table 1. Stroop interference scores by supplement dose and MCI status (data are expressed 
as mean ± SE).  
 
Supplement dose MCI status Mean SE N 
0mg MCI 3.12 0.47 7 
 Non-MCI 2.28* 0.09 29 
 Total 2.44 0.12 36 
1600mg MCI 2.30† 0.4 7 
 Non-MCI 2.39 0.10 29 
 Total 2.37 0.11 36 
2400mg MCI 2.89 0.31 7 
 Non-MCI 2.31* 0.10 29 
 Total 2.42 0.11 36 
 
* = significant difference within dose between MCI and non-MCI (p<0.05), †=significant 
difference between 0mg and 1600mg in those with MCI (p<0.05). 





Table 2: Errors on the Stroop colour-naming trial by supplement dose and MCI status (data 
are expressed as mean ± SE).  
 
Supplement dose MCI status Mean SE N 
0mg MCI 9.00 3.0 7 
 Non-MCI 2.13*‡ 0.59 29 
 Total 3.39 .083 36 
1600mg MCI 4.14† 2.5 7 
 Non-MCI 0.55* 0.21 29 
 Total 1.21# 0.51 36 
2400mg MCI 8.14 2.6 7 
 Non-MCI 2.87*‡ 0.64 29 
 Total 3.84 0.77 36 
 
* = significant difference within dose between MCI and non-MCI (p<0.05), †=significant 
difference between 0mg and 1600mg in those with MCI (p<0.05), #=significant difference 
from 0 mg and 2400 mg dose in the total group (p<0.05), ‡ significant different from 1600mg 
no MCI (p<0.05) 
MCI, Mild cognitive impairment, SE, standard error 
 
 
